原发性肝癌(HCC)TACE治疗前后p16、AFP、sVEGF的动态变化

摘要

目的:探讨HCC患者经肝动脉灌注化疗栓塞术(TACE)治疗前、后p16基因甲基化、AFP和sVEGF变化的临床意义.方法:采用甲基化特异性PCR(MSP)法检测56例HCC患者血清p16基因甲基化率,ELISA法检测AFP和sVEGF.结果:HCC患者血清p16基因甲基化检出率为69.6％(39/56),AFP阳性检出率为80.4％ (45/56),sVEGF阳性检出率为73.2％ (41/56).结论:血清DNA中p16基因甲基化检测可作为HCC分子诊断标志,三者联合检测对肝癌诊断有实用价值.%Objective:To investigate the clinical significance of p16 gene methylation status with AFP and serum VEGF before and after hepatic artery chemoembolization (TACE) treatment of HCC patients.Methods:To use methylation specific PCR (MSP) to determine serum p16 gene methylation rate,ELISA detection for AFP and serum VEGF in 56 patients with HCC.Results:Serum p16 gene methylation detection rate was 69.6％ (39/56),AFP positive detection rate was 80.4％ (45/56),serum VEGF positive rate was 73.2％ (41/56) in 56 patients with HCC.Conclusion:p16 gene methylation detection in the serum DNA can be used as diagnostic marker of HCC molecule,it has practical value in the combined detection for HCC diagnosis.